   |
|
Selecta is committed to building a leading portfolio of an entirely novel class of vaccines for antigen-specific immune activation and antigen-specific immune tolerance. To meet this objective, the company has implemented a well-defined strategy that guides the identification and execution of potential partnerships to expand its growing pipeline.
Selecta is actively seeking potential partnerships including in-licensing or out-licensing opportunities that would be consistent with the portfolio strategy. Areas of interest include vaccines for infectious diseases, cancer vaccines, tolerogenic vaccines for treatment of autoimmune diseases and allergies, and other therapeutic vaccines in neurosciences and cardiology.
In 2011, Selecta was awarded a subcontract by Science Applications International Corporation (SAIC) to develop a targeted antigen-specific synthetic vaccine particle product for malaria. Part of a larger US Federal Government initiative to develop and commercialize novel therapeutics and vaccines for malaria, Selecta's development efforts will be funded under SAIC's prime contract (number N01.AI.05421) with the National Institutes of Allergy and Infectious Diseases' (NIAID)Division of Microbiology and Infectious Diseases (DMID), which is part of the National Institutes of Health. Click here to learn more about about this collaboration.
In 2010, Selecta was awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of a therapeutic vaccine for the treatment of smoking cessation and relapse prevention. Click here to learn more about this collaboration.
In 2011, Selecta formed a research collaboration with The Juvenile Diabetes Research Foundation (JDRF) to support the development of targeted synthetic vaccines for the induction of antigen-specific immune tolerance for treatment of patients with juvenile diabetes (type 1 or insulin dependent diabetes mellitus), an autoimmune disorder. Click here to learn more about this collaboration. Link to press release on Selecta's site.
For further information about Selecta and the company's partnering and collaboration opportunities, please contact bd@selectabio.com.